First-line therapy in adult Crohn's disease: Who should receive anti-TNF agents?

Laurent Peyrin-Biroulet, Gionata Fiorino, Anthony Buisson, Silvio Danese

Research output: Contribution to journalArticlepeer-review


Therapy for Crohn's disease has long been based on a step-up approach, with monoclonal antibodies against TNF as a final option before surgery. Despite the introduction of these monoclonal antibodies, no major changes have occurred in the natural history of Crohn's disease, with half of all patients still requiring intestinal resection at 10 years. Labelling for anti-TNF agents does not take into account prognostic factors. In this Review, we propose that treatment of Crohn's disease be based on the following three disease stages: mild, moderate and severe. In patients with Crohn's disease who have complicated disease or bowel damage, and with poor prognostic factors and/or severe disease, anti-TNF treatment should be considered as first-line therapy. For patients living in areas of high risk of developing tuberculosis, as well as for patients with mild-to-moderate Crohn's disease without poor prognostic factors and with uncomplicated disease, steroids and thiopurine should be the first-line therapy. By treating patients with Crohn's disease in accordance with these disease stages, we might be able to alter disease course and reduce overtreatment. Upcoming disease-modification trials are expected to provide information to guide decision-making, ultimately changing the course of disease and improving patient quality of life.

Original languageEnglish
Pages (from-to)345-351
Number of pages7
JournalNature Reviews Gastroenterology and Hepatology
Issue number6
Publication statusPublished - Jun 2013

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'First-line therapy in adult Crohn's disease: Who should receive anti-TNF agents?'. Together they form a unique fingerprint.

Cite this